Mar 8 |
XOMA GAAP EPS of -$4.04 misses by $1.99, revenue of $4.76M misses by $1.74M
|
Mar 8 |
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
|
Feb 28 |
XOMA to Present at Upcoming Investor Conferences in March
|
Feb 16 |
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma
|
Feb 16 |
Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share
|
Feb 16 |
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
|
Jan 20 |
With 37% ownership, XOMA Corporation (NASDAQ:XOMA) has piqued the interest of institutional investors
|
Jan 18 |
XOMA expands portfolio with DSUVIA acquisition; shares tick lower
|
Jan 18 |
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
|
Jan 12 |
Xoma to pay $1M to LadRx as rare disease therapy undergoes FDA review
|